PRIMATE VASCULAR-RESPONSES TO OCTIMIBATE, A NONPROSTANOID AGONIST AT THE PROSTACYCLIN RECEPTOR

被引:22
作者
MERRITT, JE
BROWN, AM
BUND, S
COOPER, DG
EGAN, JW
HALLAM, TJ
HEAGERTY, AM
HICKEY, DMB
KAUMANN, AJ
KEEN, M
KELLY, E
KENNEY, CA
NICHOLS, AJ
SMITH, EF
SWAYNE, GTG
MACDERMOT, J
RINK, TJ
机构
[1] ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,LONDON W12 0NN,ENGLAND
[2] SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406
[3] LEICESTER ROYAL INFIRM,DEPT MED,LEICESTER LE2 7LX,ENGLAND
[4] UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND
[5] UNIV BRISTOL,DEPT PHARMACOL,BRISTOL BS8 1TD,AVON,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1111/j.1476-5381.1991.tb12163.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Octimibate is a potent inhibitor of human platelet aggregation, and appears to act (at least in part) through the prostacyclin receptor, as described in the preceding paper. Here, the vascular effects, both in vitro and in vivo, of octimibate have been compared to those of the stable prostacyclin (PGI2) mimetic, iloprost. Since octimibate shows extensive species variation and is potent at inhibiting platelet aggregation in primates, all of the experiments reported here have been carried out with primate tissue or in vivo in cynomolgus monkeys. 2 Activation of adenylyl cyclase in human lung membranes appears to involve stimulation of the vascular PGI2 receptor. Octimibate, as well as iloprost, stimulates adenylyl cyclase in this preparation. The EC50 values for iloprost and octimibate are 50 nM and 340 nM respectively. These values are similar to those seen with human platelet membranes. As with platelets, the maximal activation achievable with octimibate is 60% of that seen with iloprost. This result suggests that octimibate is a partial agonist for stimulation of adenylyl cyclase. 3 Iloprost (10-100 nM) relaxes human coronary and mesenteric artery precontracted with KC1, and also relaxes cynomolgus monkey aorta precontracted with phenylephrine. Octimibate appears to be a partial agonist for relaxation of human coronary artery precontracted with KC1; the intrinsic activity of octimibate (10-mu-M) is 0.15 compared to iloprost, and octimibate surmountably antagonizes the relaxant effects of iloprost with a K(p) of 200 nM. Octimibate (up to 10-mu-M) evokes only weak relaxation of human mesenteric artery (precontracted with KC1) and cynomolgus monkey aorta (precontracted with phenylephrine). 4 The effects of iloprost and octimibate were compared in vivo in cynomolgus monkeys. In addition to inhibiting ex vivo platelet aggregation, both compounds cause hypotension with little effect on heart rate. The dose-response curves for inhibition of ex vivo platelet aggregation and a fall in mean arterial blood pressure were compared. The dose-separation (i.e., the relative differences in effective concentrations) for the two responses is similar with both iloprost and octimibate. 5 Since the peripheral resistance vessels are intimately involved in regulation of systemic arterial blood pressure, the effects of both agents were tested on human peripheral resistance vessels (150-400-mu-m diameter) in vitro. These vessels are relaxed by both iloprost and octimibate following precontraction with KC1. The IC50 value for iloprost is 44 nM, and 1.7-mu-m octimibate evokes 50% of the maximal relaxation obtained with iloprost. Thus, the relative potencies of the two compounds in relaxing human subcutaneous resistance vessels are similar to their relative potencies in inhibiting platelet responses. This result correlates with the lack of platelet versus vascular selectivity seen with the in vivo monkey studies. 6 These results suggest that octimibate, a partial agonist at the prostacyclin receptor, is unable to discriminate between platelet and vascular prostacyclin receptors in primates.
引用
收藏
页码:260 / 266
页数:7
相关论文
共 25 条
[1]   EVIDENCE FOR INCREASED MEDIA THICKNESS, INCREASED NEURONAL AMINE UPTAKE, AND DEPRESSED EXCITATION CONTRACTION COUPLING IN ISOLATED RESISTANCE VESSELS FROM ESSENTIAL HYPERTENSIVES [J].
AALKJAER, C ;
HEAGERTY, AM ;
PETERSEN, KK ;
SWALES, JD ;
MULVANY, MJ .
CIRCULATION RESEARCH, 1987, 61 (02) :181-186
[2]   MORPHOLOGICAL AND FUNCTIONAL-CHARACTERISTICS OF ISOLATED RESISTANCE VESSELS IN ADVANCED UREMIA [J].
AALKJAER, C ;
PEDERSEN, EB ;
DANIELSEN, H ;
FJELDBORG, O ;
JESPERSEN, B ;
KJAER, T ;
SORENSEN, SS ;
MULVANY, MJ .
CLINICAL SCIENCE, 1986, 71 (06) :657-663
[3]   FUNCTIONAL AND LIGAND-BINDING STUDIES SUGGEST HETEROGENEITY OF PLATELET PROSTACYCLIN RECEPTORS [J].
ARMSTRONG, RA ;
LAWRENCE, RA ;
JONES, RL ;
WILSON, NH ;
COLLIER, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 97 (03) :657-668
[4]  
BELCH JJF, 1983, LANCET, V1, P313
[5]   (5Z)-CARBACYCLIN DISCRIMINATES BETWEEN PROSTACYCLIN-RECEPTORS COUPLED TO ADENYLATE-CYCLASE IN VASCULAR SMOOTH-MUSCLE AND PLATELETS [J].
CORSINI, A ;
FOLCO, GC ;
FUMAGALLI, R ;
NICOSIA, S ;
NOE, MA ;
OLIVA, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 90 (01) :255-261
[6]   PROSTACYCLIN ANALOGS REDUCE ADP-RIBOSYLATION OF THE ALPHA-SUBUNIT OF THE REGULATORY GS-PROTEIN AND DIMINISH ADENOSINE (A2) RESPONSIVENESS OF PLATELETS [J].
EDWARDS, RJ ;
MACDERMOT, J ;
WILKINS, AJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 90 (03) :501-510
[7]  
Gryglewski R.J., 1987, PROSTACYCLIN ITS STA
[8]  
GRYGLEWSKI RJ, 1987, PROSTACYCLIN ITS STA, V6, P3
[9]   RELAXATION OF ISOLATED HUMAN PULMONARY MUSCLE PREPARATIONS WITH PROSTACYCLIN (PGI2) AND ITS ANALOGS [J].
HAYELEGRAND, I ;
BOURDILLAT, B ;
LABAT, C ;
CERRINA, J ;
NOREL, X ;
BENVENISTE, J ;
BRINK, C .
PROSTAGLANDINS, 1987, 33 (06) :845-854